Patents Assigned to Ionis Pharmaceuticals, Inc.
-
Publication number: 20240325425Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use for selectively reducing the amount or activity of HTT RNA comprising SNP rs7685686 in a cell or subject, and in certain instances reducing the amount of mutant HTT protein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful to ameliorate at least one symptom or hallmark of Huntington's disease.Type: ApplicationFiled: February 16, 2024Publication date: October 3, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth
-
Publication number: 20240316092Abstract: Provided are compounds, methods, and pharmaceutical compositions for increasing the amount or activity of STMN2 RNA in a cell or animal, and in certain embodiments increasing the amount of STMN2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include ataxia, neuropathy, synaptic dysfunction, deficits in cognition, and decreased longevity. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and dementia with Lewy bodies (DLB).Type: ApplicationFiled: October 24, 2023Publication date: September 26, 2024Applicants: Ionis Pharmaceuticals, Inc., Ludwig Institute For Cancer ResearchInventors: Huynh-Hoa Bui, Don W. Cleveland, Ze'ev Melamed
-
Publication number: 20240318183Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.Type: ApplicationFiled: October 18, 2023Publication date: September 26, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Huynh-Hoa Bui
-
Publication number: 20240309452Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).Type: ApplicationFiled: October 16, 2023Publication date: September 19, 2024Applicants: Ionis Pharmaceuticals, Inc., The University of British ColumbiaInventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
-
Publication number: 20240309374Abstract: Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.Type: ApplicationFiled: October 24, 2023Publication date: September 19, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Gene Hung, C. Frank Bennett
-
Publication number: 20240301411Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of APP RNA in a cell or a subject, and in certain instances reducing the amount of APP protein in a cell or a subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease or disorder associated with APP. Such symptoms and hallmarks include cognitive impairment, including a decline in memory and language skills, behavioral and psychological symptoms such as apathy and lack of motivation, gait disturbances, seizures, progressive dementia, and abnormal amyloid deposits.Type: ApplicationFiled: February 16, 2024Publication date: September 12, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Hien Thuy Zhao, Punit P. Seth
-
Publication number: 20240301415Abstract: Provided are oligomeric compounds and pharmaceutical compositions for increasing the amount or activity of UNC13A RNA in a cell or animal, and/or decreasing the amount of UNC13A RNA that includes a cryptic exon in a cell or animal, and in certain instances increasing the amount of UNC13A protein in a cell or animal. Such oligomeric compounds and pharmaceutical compositions are useful to treat neurodegenerative diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.Type: ApplicationFiled: May 20, 2022Publication date: September 12, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Ruben E. Valas, Kar Yun Karen Ling
-
Publication number: 20240301412Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 RNA in a cell or animal, and in certain embodiments reducing the amount of ATXN3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include motor dysfunction, aggregation formation, and neuron death. Such neurodegenerative diseases include spinocerebellar ataxia type 3(SCA3).Type: ApplicationFiled: October 12, 2023Publication date: September 12, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventor: Susan M. Freier
-
Publication number: 20240294920Abstract: Provided herein are methods, antisense agents, specific inhibitors, and compositions useful for reducing expression or activity of NADPH oxidase 4 (hereinafter referred to as NOX4) in a subject. Also, provided herein are methods, antisense agents, specific inhibitors, and compositions that can be useful in treating NOX4-related diseases or conditions in a subject. Such methods, antisense agents, specific inhibitors, and compositions can be useful, for example, to treat a pulmonary disease in a subject.Type: ApplicationFiled: June 30, 2022Publication date: September 5, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Jeffrey R. Crosby, Chenguang Zhao, Alexey Revenko, Shuling Guo
-
Publication number: 20240294923Abstract: The present disclosure provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, certain oligomeric compounds selectively reduce the expression of a target nucleic acid transcript relative to a non-target nucleic acid transcript.Type: ApplicationFiled: August 11, 2023Publication date: September 5, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze
-
Publication number: 20240287520Abstract: The present disclosure provides methods of synthesizing modified oligonucletodies and oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group. In certain embodiments, the present disclosure provides stabilized formulations of certain sulfonyl azides for use in the synthesis of olignonucleotides comprising one or more sulfonyl phosphoramidate linkages. Some embodiments provide stabilized compositions of high energy reagents that may be used in the synthesis of modified oligonucleotides, allowing for safe process scale preparation thereof.Type: ApplicationFiled: June 29, 2022Publication date: August 29, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventor: Andrew A. Rodriguez
-
Publication number: 20240287513Abstract: Provided are compounds, methods, and pharmaceutical compositions for modulating splicing of a pre-mRNA in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a disease or disorder.Type: ApplicationFiled: August 1, 2023Publication date: August 29, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Frank Rigo, Paymaan Jafar-Nejad
-
Publication number: 20240279664Abstract: The present disclosure provides half duplex compounds comprising a first oligomeric compound and a second, shorter, oligomeric compound, wherein the first oligomeric compound is complementary to a target nucleic acid and the second oligomeric compound is complementary to the first oligomeric compound. In certain embodiments, the compounds disclosed herein are useful for modulating the expression of extra-hepatic target nucleic acids.Type: ApplicationFiled: June 27, 2023Publication date: August 22, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth, Frank Rigo, Chrissa A. Dwyer
-
Publication number: 20240279654Abstract: Provided are oligomeric agents, oligomeric compounds, antisense agents, and pharmaceutical compositions for reducing the amount or activity of PTBP 1 RNA in a cell or animal, and in certain instances reducing the amount of PTBP 1 protein in a cell or animal. Such oligomeric agents, oligomeric compounds, antisense agents, and pharmaceutical compositions are useful to treat neurodegenerative diseases or disorders such as, but not limited to, Parkinson's disease, Huntington's disease, or Alzheimer's disease.Type: ApplicationFiled: May 20, 2022Publication date: August 22, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventor: Ruben E. Valas
-
Publication number: 20240247260Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.Type: ApplicationFiled: July 11, 2023Publication date: July 25, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
-
Patent number: 12043831Abstract: Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.Type: GrantFiled: September 17, 2020Date of Patent: July 23, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventor: Susan M. Freier
-
Patent number: 12042510Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.Type: GrantFiled: December 17, 2021Date of Patent: July 23, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventors: Tianyuan Zhou, Youngsoo Kim, Robert MacLeod, Huynh-Hoa Bui, Susan M. Freier
-
Publication number: 20240229042Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of KCNT1 RNA in a cell or subject, and in certain instances reducing the amount of KCNT1 protein in a cell or subject. These compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurological condition. Such symptoms and hallmarks include seizures, encephalopathy, and behavioral abnormalities. Non-limiting examples of neurological conditions that benefit from these compounds, methods, and pharmaceutical compositions are epilepsy of infancy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome, and Ohtahara syndrome.Type: ApplicationFiled: June 25, 2021Publication date: July 11, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventor: Paymaan Jafar-nejad
-
Patent number: 12030910Abstract: In certain embodiments, the present disclosure provides compounds and methods of increasing the amount or activity of a target protein in a cell. In certain embodiments, the compounds comprise a translation suppression element inhibitor. In certain embodiments, the translation suppression element inhibitor is a uORF inhibitor. In certain embodiments, the uORF inhibitor is an antisense compound.Type: GrantFiled: September 15, 2020Date of Patent: July 9, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventors: Stanley T. Crooke, Xue-hai Liang, Wen Shen
-
Publication number: 20240209364Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLP1 RNA in a cell or subject, and in certain instances reducing the amount of proteolipid protein 1 in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a leukodystrophy. Such symptoms and hallmarks include hypotonia, nystagmus, optic atrophy, respiratory distress, motor delays, cognitive dysfunction, speech dysfunction, spasticity, ataxia, seizures, choreiform movements, and death. Such leukodystrophies include Pelizaeus-Merzbacher disease.Type: ApplicationFiled: June 26, 2023Publication date: June 27, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventor: Berit Elissa Powers